Concordance between biomarkers in cerebrospinal fluid (CSF), brain positron emission tomography with 18‐fluorodeoxyglucose (18F‐FDG‐PET) and clinical diagnosis in patients with cognitive impairment
Alberto Jose Mimenza, Karen Leon del Ángel, Rodrigo Hernández Martínez, Sara Gloria Aguilar‐Navarro · 2025
Read Concordance between biomarkers in cerebrospinal fluid (CSF), brain positron emission tomography with 18‐fluorodeoxyglucose (18F‐FDG‐PET) and clinical diagnosis in patients with cognitive impairment by Alberto Jose Mimenza, Karen Leon del Ángel, Rodrigo Hernández Martínez, Sara Gloria Aguilar‐Navarro (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11715336.txt.
Description
Alberto Jose Mimenza and three co-authors check how well spinal fluid tests, brain scans, and clinical judgment agree when sorting out memory loss, in this 2025 study. Telling Alzheimer's disease from other dementias is hard, and guidelines endorse biomarker tests to raise certainty. The team reviewed patients worked up at a national institute in Mexico between 2018 and 2023.
Seventy-seven patients had both the fluid markers and a glucose based brain scan. The two test families agreed in eighty-eight percent of cases on Alzheimer's versus other causes. Agreement between the first clinical impression and scan patterns was only moderate. Nearly half the patients had their diagnosis changed once the biomarkers came in. Where doubt remains, the authors advise using both tests rather than either alone.
Catalog record
| CREATOR | Alberto Jose Mimenza, Karen Leon del Ángel, Rodrigo Hernández Martínez, Sara Gloria Aguilar‐Navarro |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |